The Role of Estimated Glomerular Filtration Rate (eGFR) in Cost-Effectiveness (CE) Analyses Using Canagliflozin (CANA) vs. Sulfonylurea (SU) to Treat Type 2 Diabetes Mellitus (T2DM)

被引：0

作者：

Neslusan, Cheryl

Willis, Michael

Johansen, Pierre

Schroeder, Melanie

Nilsson, Andreas

Chan, Edmond

Asseburg, Christian

Schubert, Agata

机构：

来源：

DIABETES | 2016年 / 65卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1255-P

引用

页码：A329 / A329

页数：1

共 50 条

[1] Effect of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) Based on Age and Estimated Glomerular Filtration Rate (eGFR)
Gilbert, Richard E.
Weir, Matthew R.
Fioretto, Paola
Law, Gordon
Usiskin, Keith
Meininger, Gary
[J]. DIABETES, 2014, 63 : A267 - A267
[2] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
Martin, Silas
Neslusan, Cheryl
Vo, Lien
Teschemaker, Anna
Johansen, Pierre
Willis, Michael
[J]. DIABETES, 2014, 63 : A310 - A310
[3] Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Sulfonylurea (SU) Monotherapy: A CANVAS Substudy
Fulcher, Greg
Matthews, David
Perkovic, Vlado
Mahaffey, Kenneth W.
Weiss, Robert
Rosenstock, Julio
Capuano, George
Desai, Mehul
Shaw, Wayne
Vercruysse, Frank
Meininger, Gary
Neal, Bruce
[J]. DIABETES, 2013, 62 : A292 - A292
[4] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY
Erhardt, W.
Bergenheim, K.
Townsend, R.
Puelles, Fernandez de Troconiz J.
McEwan, P.
[J]. VALUE IN HEALTH, 2010, 13 (07) : A291 - A292
[5] COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL
Pititto, L.
Neslusan, C.
Teschemaker, A. R.
Johansen, P.
Willis, M.
Asano, E.
Puig, A.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A864 - A864
[6] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SAXAGLIPTIN (SAXA) AMONG OLDER INDIVIDUALS LIVING WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CANADA
Teschemaker, A. R.
Neslusan, C.
Sabapathy, S.
Yoong, K.
Johansen, P.
Willis, M.
[J]. VALUE IN HEALTH, 2015, 18 (03) : A62 - A63
[7] Cost-Effectiveness Analysis of Canagliflozin (CANA) vs. Maximally Titrated Glimepiride (GLIM) as an Add-on to Metformin (MET) in Patients with Type 2 Diabetes Mellitus (T2DM) in the United States
Neslusan, Cheryl
Martin, Silas
Teschemaker, Anna
Vo, Lien
Johansen, Pierre
Willis, Michael
[J]. DIABETES, 2014, 63 : A309 - A310
[8] The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK
Thompson, G.
Schroeder, M.
Neslusan, C.
Willis, M.
Johansen, P.
Teschemaker, A.
[J]. DIABETOLOGIA, 2014, 57 : S330 - S330
[9] Genital Mycotic Infections With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
Nyirjesy, Paul
Sobel, Jack
Fung, Albert
Gassmann-Mayer, Cristiana
Ways, Kirk
Usiskin, Keith
[J]. DIABETES, 2013, 62 : A276 - A276
[10] Canagliflozin (CANA) Improves Risk Factors of Metabolic Syndrome (MetS) vs. Sitagliptin (SITA) in Patients with Type 2 Diabetes Mellitus (T2DM) and MetS on Background Metformin (MET) plus Sulfonylurea (SU)
Davies, Michael J.
Merton, Katherine
Vijapurkar, Ujjwala
Balis, Dainius
Desai, Mehul
[J]. DIABETES, 2016, 65 : A286 - A286

← 1 2 3 4 5 →